A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Bao-Zhong Zhang, Xiaolei Wang, Shuofeng Yuan, Wenjun Li, Ying Dou, Vincent Kwok-Man Poon, Chris Chung-Sing Chan, Jian-Piao Cai, Kenn KaHeng Chik, Kaiming Tang, Chris Chun-Yiu Chan, Ye-Fan Hu, Jing-Chu Hu, Smaranda Ruxandra Badea, Hua-Rui Gong, Xuansheng Lin, Hin Chu, Xuechen Li, Kelvin Kai-Wang To, Li Liu, Zhiwei Chen, Ivan Fan-Ngai Hung, Kwok Yung Yuen, Jasper Fuk-Woo Chan, Jian-Dong Huang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19
SARS-CoV-2
linker-immunodominant site
spike protein
vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2021.1921621
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2021.1921621

Similar Items